Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial

SelfRugger · 2026-02-27T22:36:50+00:00

Novo Nordisk's obesity drug CagriSema was found less effective than Eli Lilly's tirzepatide in a head-to-head trial, achieving a 23% weight reduction compared to 25.5% for tirzepatide. This setback impacts Novo's position in the weight-loss market.

SelfRugger

2026-02-27 22:36:50

Abstract generation in progress

Novo Nordisk’s obesity drug CagriSema falls short against Eli Lilly’s in trial

FILE PHOTO: The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, December 3, 2025. REUTERS/Tom Little//File Photo · Reuters

Reuters

Mon, February 23, 2026 at 7:11 PM GMT+9 1 min read

In this article:

                                      StockStory Top Pick

LLY

-1.34%

 NOVO-B.CO  

 -11.59%

COPENHAGEN, Feb 23 (Reuters) - Novo Nordisk said on Monday its next-generation obesity drug CagriSema ‌was less effective than Eli Lilly’s tirzepatide ‌in a head-to-head trial, a setback in the race for dominance in the weight-loss drug market.

The trial was designed to show CagriSema was at least as effective as tirzepatide in reducing weight, but ‌failed to meet ⁠that goal, Novo said in a statement.

The outcome is a blow to Novo ⁠Nordisk, which is fighting to regain its lost first-mover advantage in the lucrative obesity treatment market, where demand for drugs with higher efficacy is ‌surging.

Novo Nordisk’s share price fell 11% by 1002 GMT.

Novo Nordisk said CagriSema achieved a 23% reduction in body weight over 84 weeks, compared to 25.5% for Eli Lilly’s tirzepatide in the trial.

The ‌results mean Novo’s next-generation treatment delivered less weight loss than Eli Lilly’s drug, which is already on the ‌market under the brand name Zepbound and Mounjaro.

Additional trials are exploring the full weight loss potential of CagriSema, including higher-dose combinations, Novo Nordisk ‌in its statement.

Lilly shares rose 4% to $1049.94 in U.S. premarket trading.

(Reporting by Stine Jacobsen, editing by Terje Solsvik)

Condiciones y Política de privacidad

Privacy Dashboard

More Info

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes